The appointment comes as Biocaptiva prepares to scale up its commercial operations, initially focusing on the United States. The company’s flagship msX platform extracts cell-free DNA (cfDNA) from blood to support liquid biopsies, with potential applications in cancer research and non-invasive genetic testing. "As we now focus on scaling internationally and delivering the commercial potential of our platform, Stephane's experience and reputation across the global diagnostics industry will be invaluable. Sarah Hardy, director and head of new investment at Archangels, said: "BIOCAPTIVA is going from strength to strength and is poised to accelerate towards its commercial potential under Stephane’s strategic leadership. "Archangels is proud to support BIOCAPTIVA and its vision for faster, better and deeper iteration and research on cancer, leading to better outcomes for potentially millions of people globally."